TMS (Transcranial Magnetic Stimulation) in Neurorehabilitation

Mechanisms and protocols: 1) Basic mechanism - electromagnetic coil generates rapidly changing magnetic field (~1.5 Tesla peak), which induces electric field in brain tissue, depolarizing cortical neurons; figure-of-eight coils provide focal stimulation, circular coils more diffuse, H-coil for deeper structures (deep TMS); 2) Single-pulse TMS - assesses motor evoked potentials (MEP), motor threshold, conduction time; primarily diagnostic and research; 3) Paired-pulse TMS - measures intracortical inhibition (SICI, LICI) and facilitation (ICF), interhemispheric inhibition (IHI); 4) Repetitive TMS (rTMS) - therapeutic; high-frequency (5-20 Hz) increases cortical excitability and induces LTP-like changes; low-frequency (≤1 Hz) decreases excitability and induces LTD-like changes; effects outlast stimulation period; typical session: 1500-3000 pulses, 20-40 minutes; treatment courses 5-30 sessions; 5) Theta-burst stimulation (TBS) - 50 Hz triplets at 5 Hz; iTBS (intermittent, 600 pulses in 3 minutes) - facilitating; cTBS (continuous, 600 pulses in 40 seconds) - inhibitory; rapid sessions but similar plasticity effects; 6) Quadripulse stimulation, paired associative stimulation, theta-priming - other emerging protocols; 7) Patterned stimulation - synchronizing with motor task or behavioral protocols enhances effects; 8) Safety - seizure risk in normal subjects very low (<0.01% per 1000 pulses); higher in pre-existing risk (epilepsy, brain injury, certain medications) requires careful protocol modifications; magnetic field interactions with metal implants near coil contraindicated; 9) Side effects - mild headache (10-30%), scalp pain at site, fatigue, transient hearing threshold shifts (use ear protection); rare seizures; vasovagal events.

Stroke neurorehabilitation: 1) Stroke motor recovery rationale - interhemispheric imbalance theory (contralesional cortex over-active inhibits ipsilesional), bimodal theory (mild stroke benefits from contralesional inhibition, severe needs ipsilesional excitation), bihemispheric stimulation; 2) Contralesional inhibition - low-frequency rTMS (1 Hz) or cTBS over contralesional M1 to inhibit; demonstrated benefit in motor recovery, particularly upper extremity, in subacute and chronic stroke; combined with task-specific motor training enhances efficacy; meta-analyses show small-moderate effect sizes; 3) Ipsilesional excitation - high-frequency rTMS (10 Hz) or iTBS over ipsilesional M1; particularly for severe stroke or when contralesional cortex compensatory; 4) Bihemispheric protocols - inhibit contralesional + excite ipsilesional in same session; theoretical advantage but mixed results; 5) Aphasia - low-frequency rTMS over right Broca homologue (right inferior frontal gyrus pars triangularis); benefits in chronic non-fluent aphasia (8-15% improvement in Boston Naming Test); high-frequency rTMS over left intact language regions emerging; 6) Neglect - bilateral parietal stimulation, low-frequency over contralesional posterior parietal cortex; promising for hemispatial neglect after right hemispheric stroke; 7) Dysphagia - high-frequency rTMS over pharyngeal motor cortex; emerging evidence; 8) Cognition - prefrontal cortex stimulation for attention, working memory, depression post-stroke; 9) Combined with rehabilitation - motor training during/after rTMS enhances plasticity; constraint-induced movement therapy + rTMS synergistic; pre-conditioning before exercise; 10) Time course - acute (<2 weeks) limited evidence; subacute (2 weeks-6 months) most studied with positive results; chronic (>6 months) responsive to TMS, especially with combined therapy.

Other neurorehabilitation applications and future: 1) Chronic pain - high-frequency rTMS (10-20 Hz) over primary motor cortex (M1) contralateral to pain; chronic neuropathic pain (post-stroke central pain, complex regional pain syndrome, peripheral nerve injury, spinal cord injury), fibromyalgia, migraine; 5-10 sessions effective in 30-50% with significant pain reduction; deep TMS targets ACC/insula; 2) Parkinson disease - bilateral M1 rTMS for bradykinesia (high-frequency); deep TMS (H-coil) for primary motor and dorsolateral prefrontal cortex; modest gait, bradykinesia improvements; 3) Multiple sclerosis - rTMS for fatigue (high-frequency M1), spasticity (low-frequency M1); pilot studies; 4) Cerebellar TMS - emerging for ataxia, dystonia, balance; 5) Spinal cord injury - corticospinal tract rTMS for motor recovery, neuropathic pain; 6) Tinnitus - low-frequency over auditory cortex; modest improvements in 30-40%; 7) Anxiety, OCD, PTSD - prefrontal/dorsolateral; 8) Smoking, alcohol use disorder - prefrontal/insular; 9) Treatment-resistant depression - well-established (FDA approved); high-frequency left dorsolateral prefrontal cortex 5 days/week × 4-6 weeks; iTBS comparable in 3-min daily sessions; deep TMS for severe; 10) Future developments - precision targeting with neuronavigation and individualized targets, combined with EEG/fMRI biomarkers, accelerated protocols (multiple sessions per day), home-use simplified devices, portable TMS, theranostic combinations, personalized medicine approaches based on connectome and biomarker data, integration with virtual reality and rehabilitation systems, broader insurance coverage, lower-cost devices.